Brainstorm Cell Therapeutics Inc. (BCLI)
Automate Your Wheel Strategy on BCLI
With Tiblio's Option Bot, you can configure your own wheel strategy including BCLI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BCLI
- Rev/Share 0.0
- Book/Share -1.2641
- PB -0.8702
- Debt/Equity -0.0927
- CurrentRatio 0.0429
- ROIC 1.7725
- MktCap 8732768.0
- FreeCF/Share -1.4805
- PFCF -0.9604
- PE -0.5813
- Debt/Assets 0.393
- DivYield 0
- ROE 2.0304
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2025 Earnings Call Transcript
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Joyce Lonergan - Investor Relations, LifeSci Advisors Chaim Lebovits - President & Chief Executive Officer Haro Hartounian - Executive Vice President & Chief Operating Officer Bob Dagher - Executive Vice President & Chief Medical Officer Netta Blondheim-Shraga - Senior Vice President, Research & Development Conference Call Participants Jason McCarthy - Maxim Group David Bautz - Zacks Small-Cap Operator Greetings, and welcome to the Brainstorm Cell Therapeutics First Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode.
Read More
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK , May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn® (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS).
Read More
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 7, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2025, and provide a corporate update, at 8:30 a.m. Eastern Time on Thursday, May 15, 2025.
Read More
BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
Presentation of biomarker findings from cerebrospinal fluid analyses Workshop on adaptive and decentralized ALS trial design Panel on clinical trial access and the role of patient and caregiver engagement NEW YORK , May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in the 4th Annual ALS Drug Development Summit, to take place May 12-14, 2025, in Boston, MA. The company's senior leadership team will participate in sessions that highlight insights and expertise gained throughout the NurOwn® development program, contributing to the broader conversation on the …
Read More
BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
Published: April 29, 2025 by: PRNewsWire
Sentiment: Neutral
New findings highlight impact of UNC13A genotype on treatment response in ALS NEW YORK , April 29, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, in collaboration with leading ALS research centers, today announced the acceptance of new pharmacogenomic data for oral presentation of new findings on NurOwn® at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, to take place from May 6 - 10, 2025 in New Orleans. The data highlight the impact of the UNC13A genotype on clinical outcomes for amyotrophic lateral sclerosis (ALS) …
Read More
Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Call Transcript
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Neutral
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Michael Wood - Investor Relations Chaim Lebovits - President & Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Bob Dagher - Executive Vice President & Chief Medical Officer Haro Hartounian - Executive Vice President & Chief Operating Officer Conference Call Participants Jason McCarthy - Maxim Group David Bautz - Zacks Small-Cap Operator Good morning, everyone, and welcome to BrainStorm Cell Therapeutics Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Read More
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update
Published: March 24, 2025 by: PRNewsWire
Sentiment: Neutral
Call Scheduled for March 31, 2025, at 8:30 AM Eastern Time NEW YORK , March 24, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the fourth quarter and year ended December 31, 2024, at 8.30 a.m. Eastern Time on March 31, 2025.
Read More
About Brainstorm Cell Therapeutics Inc. (BCLI)
- IPO Date 2003-10-07
- Website https://www.brainstorm-cell.com
- Industry Biotechnology
- CEO Mr. Chaim Lebovits
- Employees 27